Use of eribulin as an earlier-line chemotherapy for patients with HER2-negative metastatic breast cancer

Background: Previous prospective studies have shown that eribulin improves the survival in patients with metastatic breast cancer (MBC). However, the optimal timing of its administration to achieve the longest extended survival and the efficacy of using eribulin monotherapy as earlier-line chemother...

Descripción completa

Detalles Bibliográficos
Autores principales: Shingaki, Sumito, Kogawa, Takahiro, Shimokawa, Mototsugu, Harano, Kenichi, Naito, Yoichi, Kusuhara, Shota, Fujimoto, Yumi, Matsubara, Nobuaki, Hosono, Ako, Mukai, Hirofumi, Onishi, Tatsuya, Hojo, Takashi, Mukohara, Toru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196254/
https://www.ncbi.nlm.nih.gov/pubmed/32368292
http://dx.doi.org/10.7150/jca.37670

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196254/
https://www.ncbi.nlm.nih.gov/pubmed/32368292
http://dx.doi.org/10.7150/jca.37670

Ejemplares similares